Immunogenicity of sanofi pasteur tetravalent dengue vaccine

Journal of Clinical Virology

Volumn 46, Issue SUPPL. 2, 2009, Pages

  Guy, Bruno ^a  

^a Research Department   (France)

Author keywords

Antibody dependent enhancement; Cell mediated response; Immunogenicity; Tetravalent vaccine

Indexed keywords

DENGUE VACCINE; GAMMA INTERFERON; LIVE VACCINE; TETRAVALENT DENGUE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DENGUE; DRUG SAFETY; FLAVIVIRUS; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; TH1 CELL; TH2 CELL; VACCINATION; VIREMIA; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; DENGUE VACCINES; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; TH1 CELLS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 70349448544     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(09)70290-2     Document Type: Article

References (9)

1. Halstead S.B., and O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265 (1977) 739-741
2. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19 (2006) 429-436
3. Guirakhoo F., Arroyo J., Pugachev K.V., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75 (2001) 7290-7304
4. Guirakhoo F., Kitchener S., Morrison D., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2 (2006) 60-67
5. Deauvieau F., Sanchez V., Balas C., et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Am J Trop Med Hyg 76 (2007) 144-154
6. Guy B., Barban V., Mantel N., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80 (2009) 302-311
7. Guy B., Chanthavanich P., Gimenez S., et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22 (2004) 3563-3574
8. Guy B., Nougarede N., Begue S., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26 (2008) 5712-5721
9. Chaturvedi U.C., Agarwal R., Elbishbishi E.A., and Mustafa A.S. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 28 (2000) 183-188